Press Releases
Jun. 25, 2019 Bioasis Announces FDA Response to Pre-IND Submission
GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »
Jun. 24, 2019 Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications
U.S. Patent Office and European Patent Office issue allowances of patent applications relating to iduronate-2-sulfatase (“IDS”) polypeptide/xB3 conjugates European Patent Office issues allowance of patent application relating to trastuzumab/xB3 conjugates including xB3-001, Bioasis’ lead product in development for the treatment of HER2+ breast cancer brain metastases
May. 30, 2019 Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced… Read more »
May. 21, 2019 Bioasis Announces Closing of Previously Disclosed Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
May. 6, 2019 Bioasis Announces Private Placement
This News Release is Not for Distribution to U.S. Newswire Services or Dissemination in the United States
Mar. 25, 2019 Bioasis Technologies Inc. Announces Warrant Extension
GUILFORD, Conn. — (BUSINESS WIRE) — BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »
Mar. 11, 2019 Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer
GUILFORD, CONN., BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TMplatform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that its board of directors has appointed Dr.… Read more »
Jan. 29, 2019 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited… Read more »
Jan. 9, 2019 Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer
GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Christine Antalik as chief financial… Read more »
Jan. 7, 2019 Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology
Under the terms of the Material Transfer Agreement, Bioasis will receive $500,000